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ABSTRACT
The m etabo lism  o f ir ino tecan  (C PT-11) involves sequentia l ac tiva tion  to  SN- 
38 and d e to x ifica tio n  to  th e  pha rm a co lo g ica lly  inactive  SN-38 g lu cu ro n id e  
(S N -38C ). W e have previously  d e m onstra ted  th e  role o f UCT1A1 enzym e in 
th e  g lu cu ro n id a tio n  o f SN-38 and a s ig n ifica n t co rre la tion  be tw een  in vitro 
g lu cu ro n id a tio n  o f SN-38 and UGT1A1 gene p ro m o te r p o lym o rp h ism . This 
p o lym o rp h ism  ( UGT1A1*28) is characterized by th e  presence o f an add itio n a l 
TA repeat in th e  TATA sequence o f th e  UGT1A1 p ro m o te r, ((TA )7TAA, instead 
o f (TA )STAA). Here w e  re p o rt th e  results fro m  a prospective  c lin ica l pharm a- 
cogene tic  s tudy  to  d e te rm in e  th e  s ign ificance o f UGT1A1*28 p o lym o rp h ism  
on ir ino tecan  d ispos ition  and to x ic ity  in patients w ith  cancer. T w e n ty  patients 
w ith  solid tu m o rs  w ere  trea ted  w ith  a 90 m in  i.v. in fus ion  o f ir ino tecan  (300  
m g m 2) once every 3 weeks. The fre q u e n cy  o f UGT1A1 geno types was as 
fo llow s: 6 /6 — 45 % , 6 /7 — 35%  and 7 /7 — 20% , w ith  allele frequencies o f 
0 .3 7 5  and 0 .625  fo r  (TA )7TAA and (TA)6TAA, respectively. Patients w ith  the  
(TA )7TAA p o lym o rp h ism  had s ig n ifica n tly  lo w e r SN-38 g lu c u ro n id a tio n  rates 
than  those w ith  th e  norm a l allele (6 /6 > 6 /7 > 7 /7 ,  P =  0 .0 0 1 ). M ore  severe 
grades o f d iarrhea and neu tropen ia  w ere  observed o n ly  in patients h e te ro ­
zygous (g rade  4 d iarrhea, n =  1) o r hom ozygous (g rade 3 d ia rrhea /g rade  4 
neu tropen ia , n =  1 and grade  3 neu tropen ia , n = 1) fo r  th e  (TA )7TAA 
sequence. The results suggest th a t screening fo r  UGT1A1*28 p o lym o rp h ism  
m ay id e n tify  patients  w ith  lo w e r SN-38 g lu c u ro n id a tio n  rates and greater 
suscep tib ility  to  ir ino tecan  induced  gastro in testina l and bone m a rro w  to x ­
ic ity .
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INTRODUCTION
The topoisomerase I inhibitor, irinotecan (CPT-11, 7-ethyl-10-[4-(l-(piperidino)- 
1-piperidinolcarbonylcam ptothecin, Camptosar®) is currently approved for use 
as first-line therapy in m etastatic colorectal cancer, in com bination w ith 5-fluor- 
ouracil (5-FU) and leucovorin (LV).1 Chem otherapy w ith irinotecan is often 
accompanied by unpredictable, dose-limiting and life-threatening diarrhea and 
myelosuppression, attributed to its active metabolite, SN-38 (7-ethyl-lO- 
hydroxycam ptothecin). We have previously shown tha t SN-38 undergoes glucu­
ronide conjugation to the pharmacologically inactive SN-38 glucuronide (SN- 
38G, lO-O-glucuronyl-SN-38) by the hepatic uridine diphosphate glucuronosyl- 
transferase 1A1 (UGT1A1) enzyme.2
The glucuronidation of SN-38 may be protective against irinotecan-induced 
gastrointestinal toxicity.3 Our hypothesis is th a t this protection may be geneti­
cally determ ined, as UGT1A1 enzyme is known to exist in polym orphic states. 
Deficient or reduced expression levels of U G TlA l are observed in familial hyper-
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bilirubinem ic syndromes such as Crigler-Najjar (Type I)4 
and Gilbert's syndrom e,5 respectively. A dinucleotide repeat 
polym orphism  in the TATA sequence of the prom oter 
region of UGT1A1 has been described in Gilbert's syn­
drom e.5 The specific polym orphism  (UGT1A1*28) is the 
presence of a (TA)7TAA sequence in the prom oter region, 
instead of (TA)6TAA. In studies w ith hum an liver micro- 
somes, we have dem onstrated an association between this 
polym orphism  and SN-38 glucuronidation, w ith signifi­
cantly lower SN-38 glucuronidation rates in liver samples 
heterozygous or homozygous for the (TA)7TAA polym or­
phism .6 The current study is a prospective pharm acogenetic 
investigation of the influence of the UGT1A1*28 polym or­
phism on the disposition and toxicity of irinotecan in 
patients w ith cancer.
RESULTS
Of the 20 patients, nine (45%) patients were of genotype 
6/6, seven (35%) patients were of genotype 6/7, and four 
(20%) were of genotype 7/7 (Table 1). Allele frequencies of 
(TA)6TAA and (TA)7TAA were 0.625 and 0.375, respectively. 
This agrees w ith previous reports on the frequency of the 
(TA)7TAA allele of 0.33-0.396-8 in a Caucasian population. 
The other TA repeats ((TA)5TAA and (TA)„TAA), shown to 
be present m ainly in African subjects,6'7'9 were no t found in 
this study. The subjects in our study were predom inantly of 
Caucasian origin (;? = 18) w ith one patient each of African 
(with genotype 6/7) and Asian (with genotype 6/6) descent.
The time-course of the ratio of plasma concentration of 
SN-38G to SN-38 {|SN-38G]/|SN-38]| (Figure 1) indicated 
m uch lower glucuronidation rates of SN-38 for patients with 
genotypes 6/7 and 7/7 w hen compared to  those tha t are 
homozygous for the wild-type allele (6/6) at each blood sam­
pling time. There was a significant progressive reduction in 
SN-38 glucuronidation rates in patients w ho are hetero­
zygous (6/7) and homozygous (7/7) for the (TA)7TAA poly­
m orphism  (Table 1) (6 /6>6/7>7/7 , z  = -2 .93, P = 0.001). 
Circulating levels of SN-38 were higher in patients w ith the 
(TA)7TAA polym orphism , reflected by the significant 
increase in AUCSN„-!8 values in patients w ith 6/7 and 7/7 
genotype (7 /7>6/7>6/6 , z = 3.23, P = 0.001, Table 1). 
Patients w ith 6/7 and 7/7 genotypes had lower AUCSN.-JWi
Time (hours)
Figure 1 Time-course of plasma concentration ratios of SN-38G to 
SN-38 {[SN-38G]/[SN-38]} in patients after irinotecan treatment, 
stratified according to UCT1A1 promoter genotype. All data are the 
mean ratio in respective number of patients in each group—6/6 (n 
= 9), 6/7 (n = 7) and 7/7 (n = 4) t  SEM.__________________
values than  those w ith the 6/6 genotype, although this 
decrease was no t statistically significant (Table 1). As pre­
vious studies on the weekly schedule of irinotecan have 
indicated a significant relationship of biliary index of SN- 
38 w ith severity of diarrhea,'5 we examined the association 
between biliary index and UGT1A1*28 polymorphism. 
Patients w ith genotypes 6/7 and 7/7 had a significant trend 
toward higher biliary indices (7 /7>6/7>6/6 , z  = 3.23, P = 
0.0 0 1).
W ith regard to  toxicity, ANC nadirs significantly corre­
lated w ith AUC values for SN-38 (r = -0 .8 1 , P < 0.0001). 
There was a significant trend toward lower ANC nadir values 
in patients w ith genotypes 6/7 or 7/7 (Figure 2). All patients 
w ith two wild-type alleles (6/6) had no/low  diarrhea and 
neutropenia (grades 0 or 1). More severe grades of diarrhea 
and neutropenia were observed only in patients w ith geno­
types 6/7 (one patient w ith grade 4 diarrhea) and 7/7 (one 
patient w ith grade 3 diarrhea and grade 4 neutropenia and
Table 1 Frequency of UCT1A1 promoter genotypes and comparison of dispositional parameters of SN-38, the active 
metabolite of irinotecan





(ng / r1 m t1)
AUCo. t 
(SN-38C) 
(ng hr1 m t1)
Billiary indef
6/6 9 0.45 9.28 205.13 1631.54 2728.82
(3.77) (23.52) (459.67) (452.36)
6/7 7 0.35 4.04 288.61 1144.44 4970.91
(0.65) (25.51) (200.59) (1242.31)
7/7 4 0.20 2.41 531.37 1236.96 9685.61
(0.54) (169.82) (397.70) (2411.57)
All data are expressed as mean (SEM).
"6/6>6/7>7/7, z^ -2.93, P- 0.001; b7/7>6/7>6/6, z -  3.23, P- 0.001; r7/7>6/7>6/6, z -  3.23, P - 0.001, non-parametric trend analysis.
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Figure 2 Correlation between absolute neutrophil count (ANC) 
and UGT1A1 promoter genotypes in patients after irinotecan treat­
ment. ‘Significant trend in ANC nadirs (6/6>6/6>7/7, z = -2.05, P 
= 0.04, non-parametric trend analysis).
deaths due to  dehydration, neutropenia and sepsis after 
initiation of treatm ent w ith irinotecan com bined w ith 5- 
FU/LV.15 The results from our study may at least in part 
explain the reasons for such toxicity, w hich may be geneti­
cally determined.
We have recently extended this study to increase the irin­
otecan dose to 350 m g m  2 w ith a sample size of 60 patients. 
Besides the dinucleotide repeat polym orphism  in the pro­
m oter region, single nucleotide polym orphism s (SNPs) in 
the  coding region of UGT1A1 are also being investigated, 
such as 211G—>A, 686C—>A, 1091C—>T, w hich have been 
shown to be present only in Asian subjects.16,17 The Asian 
subject in our study who had a genotype of 6/6 (and SN- 
38 glucuronidation ratio of 6.15) did no t have the 211G—>A 
(Gly71Arg) m utation  tha t is present at high frequency (32%) 
in Asian subjects.18 Other possible pharm acogenetic deter­
m inants of irinotecan toxicity such as polym orphism s in 
metabolizing enzymes (CYP3A4/3A5 and carboxylesterase)19 
and transporters (p-glycoprotein)20,21 are also being investi­
gated in this study. Future studies should also address the 
relationship between the UGT1A1 genotype and response in 
colorectal cancer and other irinotecan-sensitive neoplasms.
one patient w ith grade 3 neutropenia). However, this differ­
ence was no t significant am ong the three genotypes (P =
0.242 for neutropenia grades and P = 0.289 for diarrhea 
grades).
DISCUSSION
The m ajor dose-limiting toxicities of irinotecan include 
diarrhea and myelosuppression (to a lesser extent). Inci­
dences of irinotecan-induced gastrointestinal toxicity can be 
severe and do no t respond adequately w ith conventional 
anti-diarrheal treatm ents.10 Irinotecan therapy is also com ­
plicated by the significant inter-subject variations in  such 
toxicity and pharm acokinetic parameter estimates.3,11 As 
glucuronidation of the active metabolite, SN-38, is a major 
determ inant of irinotecan m etabolism  and toxicity,2,3 we 
have investigated the contribution of genetic differences in 
UGT1A1 enzyme activity on irinotecan disposition and tox­
icity. Previous studies have indicated severe CPT-11 toxicity 
in  patients w ith Gilbert's syndrome, diagnosed by increased 
serum bilirubin levels.12 In a study w ith nine patients, Ando 
et a l13 observed a lower glucuronidation rate of SN-38 in  a 
patient w ith 7/7 genotype vs those w ith 6/7 (n = 1) and 6/6 
(n = 7) genotypes. A retrospective study in Japan indicated 
th a t the 6/7 and 7/7 genotypes would be a significant risk 
factor for severe irinotecan toxicity.14 The current study is 
the  first prospective clinical investigation addressing the 
influence of pharmacogenetics of UGT1A1 polym orphism  
on therapy w ith irinotecan.
Our results indicate tha t screening of patients for the 
UGT1A1*28 polym orphism  may be a useful diagnostic tool 
to  predict in vivo glucuronidation of SN-38. Patients w ith the 
(TA)7TAA repeat in the  prom oter region of UGT1A1 may be 
expected to  exhibit a higher incidence of diarrhea and neu­
tropenia th an  those w ithout the polym orphism . A recent 
report has indicated an unexpectedly high rate of early
METHODS
Patients
Twenty adult patients (10 male, 10 female) w ith solid 
tum ors (lung—seven, colon—three, esophageal and liver— 
two each, and one each of chondrosarcom a, nasopharyn­
geal, endom etrial, ovarian, rectal and neuroendocrine 
tumors) participated in  this study. Standard phase I clinical 
eligibility criteria were used to  enroll patients including 
adequate performance status (>70%  Karnofsky score), 
recovery from toxicity from previous therapy and measur­
able or evaluable disease. Inclusion criteria included WBC 
^3500, ANC >1500, platelets >100000 |xl_1, creatinine 
<1.5 m g dl"1, norm al conjugated bilirubin levels, and SCOT, 
SGPT <5 x upper lim it of norm al unless due to disease. 
Patients w ith biologic or chem otherapy w ith in  4 weeks (6 
weeks for prior treatm ent w ith nitrosoureas or m itom ycin C) 
prior to irinotecan treatm ent were excluded from the study. 
Patients w ith prior radiation therapy w ithin 4 weeks (if 
greater th an  25% of bone marrow was irradiated) or on col­
ony stim ulating factors w ith in  2 weeks were excluded. Post­
transplant patients, w om en of childbearing potential not 
practising b irth  control, pregnant or lactating w om en were 
also excluded. In addition, patients w ith history of inflam ­
m atory bowel disease requiring therapy, chronic diarrheal 
episodes or paralytic ileus were excluded from the study.
To prevent nausea and vom iting, all patients were pre- 
trcatcd w ith ondansetron (Zofran5) 20 mg, IVPB (in 50 cc 
of 5% dextrose injection, USP, given over 0.5 h), 30 m in 
prior to  irinotecan adm inistration. All patients were cau­
tioned about possible severe diarrhea and were given written 
instructions to  begin loperamide (Im odium 5) treatm ent for 
late diarrhea (occurring m ore th an  24 h  after irinotecan 
adm inistration) at a dose of 4 m g at the  first onset of late 
diarrhea and th en  2 m g every 2 h  (or every 4 h  while asleep) 
un til the  patient is diarrhea-free for at least 12 h. Irinotecan
www.nature.com/tpj
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dose was reduced by 50 mg n r 2 in patients experiencing 
grade 3 or 4 toxicities, including diarrhea and neutropenia.
Informed consent was obtained from each patient for all 
study procedures including the collection of DNA and gen­
etic analysis, in accordance w ith Federal and institutional 
guidelines.
Irinotecan Formulation and Dosing
Irinotecan solution (20 mg ml-1) was supplied by the 
N ational Cancer Institute. Appropriate dilutions were made 
in 5% dextrose solution and adm inistered to  patients by 
intravenous infusion (90 min) at a dose of 300 mg itt2, once 
every 3 weeks. This dose was selected prior to acceptance 
of 350 mg itt2 as the preferred dose on the once every 3- 
week schedule.22
Blood Sampling
Blood samples (7 ml) were collected on day 1 of cycle 1 at 
baseline and various tim e intervals—30, 60 and 90 m in dur­
ing infusion and at 10, 20, 30, 45, 60 m in and 1.5, 2, 4, 6, 
8, 12 and 24 h  after infusion of irinotecan. Plasma samples 
were separated and analyzed for the determ ination of con­
centrations of irinotecan, SN-38 and SN-38G. A blood sam­
ple (4.5 ml) was also collected at baseline for the isolation 
of DNA and U G T lA l genotyping.
Analysis of Irinotecan, SN-38 and SN-38G in Plasma
Plasma concentrations of irinotecan and its metabolites (SN- 
38 and SN-38G) were measured using a reverse phase HPLC 
m ethod w ith fluorescence detection.11 Briefly, plasma 
samples (100 (xl) were centrifuged (2500 g  for 20 min) after 
addition of m ethanol and internal standard (cam ptothecin, 
1 (xg m l-1). The supernatant was evaporated to dryness and 
reconstituted in 200 (xl mobile phase, consisting of 70% 0.1 
M potassium dihydrogen phosphate w ith 3 mM 1-hep- 
tanesulfonic acid (pH 4.0) and 30% acetonitrile. One h u n ­
dred microliter-aliquots were injected into an HPLC system 
(Hitachi Instruments, San Jose, CA, USA) coupled to a fluor­
escence detector (Xox = 375 nm  and Xt.„, = 566 nm ) and a 
(xBondapak C iS colum n (10 (xm, 3.9 x 300 mm; Waters Cor­
poration, MA, USA) w ith a mobile phase flow rate of 0.8 ml 
m in -1. SN-38G concentrations were determ ined indirectly 
as the increase in SN-38 concentrations after hydrolysis (2 
h, 25°C) of SN-38G w ith (3-glucuronidase enzyme (E. coli 
Type IX-A, Sigma-Aldrich Co, MO, USA) (1000 U m l-1 in 0.1 
M sodium phosphate buffer, pH 6.4).
UGT1A1 Genotyping Assay
U G T lA l genotyping was performed after amplification of 
isolated DNA samples by polymerase chain reaction w ith 
primers flanking the polym orphic TA locus (forward primer: 
5 '-GTCACGTGACACAG'TCAAAC-3' and reverse primer: 5'- 
TTTGCTCCTGCCAGAGGTT-3'), described previously.6-8 
Genotypes were assigned as follows: 6/6—homozygous for 
(TA)6TAA: 6/7—heterozygous w ith each of (TA)6TAA and 
(TA)7TAA; and 7/7—homozygous for (TA)7TAA.
Toxicity Measurement
Toxicity was measured using nadir values of absolute neu­
trophil counts (ANC) after the first irinotecan dose (day 12­
14) and grades of diarrhea and neutropenia, w hich were on 
a scale of 0-4, as per NCI guidelines on grading com m on 
toxicities after chem otherapy (CTC version 2.0, 
h ttp ://ctep .info .n ih .gov).
Data Analysis
Pharmacokinetic parameters were determ ined using non- 
com partm ental analysis (WinNonlin®, Pharsight Corp, 
Apex, NC, USA). The in vivo glucuronidation rate of SN-38 
(SN-38 glucuronidation ratio) was expressed as the ratio of 
the area under the plasma concentration-tim e curve until 
the last sampling poin t (AUC) for SN-38G (AUCSN„3SG) over 
tha t for SN-38 (AUCSN„3S). Biliary index of SN-38, w hich is 
a surrogate measure of SN-38 biliary excretion was calcu­
lated as (AUCsn„3S/AUCsn„3sg) x AUCa .-r.u , as described pre­
viously.3
Statistical Analysis
Statistical analysis was performed using the Stata* software 
package (Stata Corp, College Station, TX, USA). Nonpara- 
metric trend analysis23 was conducted to compare pharm a­
cokinetic parameters, glucuronidation ratios, biliary indices 
and ANC nadirs am ong patients w ith the three U G T lA l 
genotypes. Fisher's exact test was used for testing of statisti­
cal significance in diarrhea and neutropenia grades between 
genotypes. P-values <0.05 were regarded as statistically sig­
nificant and all tests were two-sided. The sample size of 20 
represents the cohort of patients treated at the dose of 300 
mg n r 2; the  protocol was subsequently am ended to  utilize 
the currently accepted dose of 350 mg i t t 2 and evaluation 
at tha t dose level is ongoing.
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ABBREVIATIONS
6/6 homozygous for (TA)6TAA
6/7 heterozygous with one each of alleles (TA)6TAA and
(TA^ TAA
7/7 homozygous for (TA)7TAA
ANC acute neutrophil count
AUC area under the plasma concentration-time curve
CPT-11 irinotecan (CPT-11,7-ethyl-10-[4-(l-(piperidino)-1 -piperid-
ino] carbonylcamptothecin)
SN-38 7-ethyl-10-hydroxycamptothecin
SN-38C SN-38 glucuronide (lO-O-glucuronyl-SN-38)
UGTlAl uridine diphosphate glucuronosyltransferase, isoform 1A1.
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